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Objectives. Mucosal melanomas are rarer than their cutaneous counterparts and are associated with a poorer prognosis. We report
the clinical outcomes of patients with mucosal melanomas of the head and neck region generally treated with deﬁnitive surgery
followed by postoperative radiation therapy (RT). Methods. We reviewed the records of 17 patients treated at the University of
Miami in 1990–2007. Patients generally received conventionally fractionated RT regimens to the postoperative bed. Elective nodal
RT was not routinely delivered. Eight patients received adjuvant chemotherapy or immunotherapy. Results. Median followup was
35.2 months (range 5–225). As the ﬁrst site of failure: 3 patients recurred locally, 2 regionally and 2 distantly. All 3 patients who
recurred locally had not received RT. Of the 5 locoregional recurrences, 4 were salvaged successfully with multimodality therapy
with no evidence of disease at last followup. Overall survival was 64.7% at 2 years and 51.5% at 5 years. Conclusions. Patients with
mucosal melanoma of the head and neck are best treated with surgery to achieve negative margins, followed by postoperative RT
to optimize local control. Elective nodal irradiation may not be indicated in all cases, as regional failures were not predominant.
Distant metastases were fewer when compared to historical data, potentially due to advancements in adjuvant therapies as well as
aggressive multi-modality salvage at time of failure.
1.Introduction
Mucosalmelanomasareexceedinglyraretumorswhichcom-
prise a small subset of all melanomas but are associated with
an even poorer prognosis than their cutaneous counterparts
[1]. While mucosal primaries account for less than 2% of
all melanomas in the United States, approximately 50% of
mucosal melanomas occurs in the head and neck region
[2]. These lesions most commonly present in the oral cavity,
nasal cavity, or paranasal sinuses, all of which are lined with
ectodermal derived mucosa. Other head and neck sites such
asthepharynxandlarynxareendodermalintheiroriginand
therefore are rarely aﬀected [3].
Despite their rarity, the aggressive nature of these tumors
has been well established, with 5-year overall survival rates
generally described as 30% at best [3–5]. The poor prognosis
is typically associated with early presentation of distant
metastases despite adequate locoregional control [1].
As these lesions are uncommonly encountered, there
remains a paucity of data to clearly delineate optimal
treatment regimens. Primary treatment has typically con-
sisted of surgery and/or radiation therapy (RT). However,2 ISRN Oncology
there remain no prospective data to formally compare
treatment modalities. Available data generally comes from
single-institution retrospective series and often includes
patients treated decades ago with older local and systemic
modalities.
The role of RT in particular remains unclear. While
adjuvant RT has been shown to improve local control in
multiple series, an improvement in survival is yet to be
observed on a consistent basis [5]. This is likely due to
an inherent selection bias, with more advanced disease
being treated with aggressive, combined-modality regimens.
This issue, along with the competing risk of potentially
lethal distant metastases in more advanced disease, makes a
survival advantage diﬃcult to demonstrate in a retrospective
setting. Furthermore, the rarity of this disease entity limits
the statistical power of single-institution series.
We report our results of a modern experience of patients
with primary mucosal melanomas of the head and neck
treated at the University of Miami from 1990–2007. We
seek to generate hypotheses in regards to the optimal
treatment paradigm for patients in the contemporary era
of advanced radiation delivery techniques, as well as in
the setting of newer systemic cytotoxic and immunologic
therapies.
2.MaterialsandMethods
We retrospectively reviewed the records of 17 patients with
primary mucosal melanomas of the head and neck treated
with a curative intent at the University of Miami and aﬃl-
iated hospitals from 1990 through 2007 in an institutional
review board-approved outcomes analysis. Patients were
included if they had a previously untreated, newly diagnosed
non metastatic primary mucosal melanoma of the head and
neck region.
Patient and disease characteristics included age, gender,
race,primarysiteofdisease,histologicsubtype,diseasestage,
andtreatmentreceived.Althoughmarginstatuswasavailable
in all cases, depth of invasion was generally not reported as
tumors are often unable to be resected en-bloc, particularly
in sinonasal sites. As no modern staging system exists for
mucosal melanomas, we retrospectively staged using the
2009 AJCC staging system for head and neck cancers based
upon the primary site of disease [6].
Overall survival (OS) was deﬁned as the time from
surgery/biopsy to death from any cause, with surviving
patients censored at date of last followup. Disease free-
dom (DF) was deﬁned as the elapsed time from date of
surgery/biopsy to earliest occurrence of local, regional, or
distant failure. Patients who died of unrelated causes were
also censored at last followup. Overall survival and disease
freedom were estimated using the Kaplan-Meier method
[7]. The rates of local, regional, and distant failures were
estimated by the method of cumulative incidence (CI) as
described by Gray [8, 9]. Statistical analyses were conducted
using SAS software version 9.2 (SAS Institute Inc., Cary,
North Carolina) and R software version 2.11.1.8. Due
to the limited patient numbers in this single-institution
retrospective analysis, subset analyses are not reported as
they are unlikely to have meaningful results. Instead, we
generally report our results using descriptive statistics.
3. Results
3.1. Patient Characteristics. Of the 17 patients, 10 (59%)
were men and 7 (41%) were women. The median age was
66 years (range, 27–84 years). Fourteen (82%) of patients
werewhiteandthree(18%)wereAfricanAmerican.Thirteen
(76%)ofpatientspresentedwithmelanoma NOS,whilefour
(24%) had a spindle-cell subtype. Median followup was 35.2
months (range 5–225) overall and 61 months in surviving
patients.
The primary site of disease was in the sinonasal cavity for
11 (65%) patients and oral cavity for 6 (35%) patients. Based
upon the 2009 AJCC guidelines for head and neck tumors,
six (35%) patients were clinically staged as having T1, one
(6%) as T2, three (24%) as T3, and ﬁve (29%) as T4 disease.
One patient’s primary tumor could not be adequately staged
and assigned a stage of Tx (6%). Fifteen (88%) patients were
clinically N0 and two (12%) were N2. All patients presented
without evidence of metastatic disease.
3.2. Treatment. Sixteen of the 17 patients (94%) underwent
surgical resection upfront while one (6%) was treated with
deﬁnitive RT. Of the 16 patients who underwent upfront
surgical resection, surgical margins were negative in 13
(81%) patients and positive in three (19%) patients. Patients
who presented with palpable neck disease underwent at
minimum an ipsilateral neck dissection. Eleven patients
(65%), received postoperative RT to the involved sites of
disease. The median radiation dose delivered was 59.4Gy
(range, 54–61.2Gy), typically in 1.8–2Gy per daily fraction
to the involved sites of disease. Hypofractionated treatment
regimens were not used. One patient (6%) however, was
treated with a hyperfractionated regimen at 1.2Gy b.i.d. and
onepatient(6%)didreceiveelectivenodalRT.Sevenpatients
(41%) received adjuvant immunotherapy while one patient
(6%)receivedadjuvantchemotherapy.Patientandtreatment
characteristics are summarized in Table 1.
3.3. Failures. Recurrence data is based upon the ﬁrst site
of failure. Overall, seven of 17 (41%) patients recurred at
present followup. Of these, three patients recurred locally,
two regionally, and two distantly. Incidentally, all three
patients who recurred locally had not received postoperative
RT (Table 2). When patients did recur locally or regionally,
they were salvaged aggressively, often with a combination of
surgery, RT, and/or systemic therapy. Using this aggressive
approach, four of the ﬁve locoregional recurrences were
salvaged successfully, with no evidence of disease at last
followup.Thepatientwhowasnotsalvagedsuccessfullywent
on to develop distant metastases and died in fewer than six
months since time of noted failure.
Based upon cumulative incidence estimates, localcontrol
at 2 years was excellent 92% and preserved at 5 years at
81%. Distant control at 2 and 5 years was 85.9% (Table 3).ISRN Oncology 3
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Table 2: Recurrences. Note that all 3 local failures occurred in
patients who did not receive postoperative radiation therapy to the
tumor bed.
Recurrence n Percentage
Yes 7 41
No 10 59
Site of recurrence
Local 3 17
Regional 2 12
Distant 2 12
Table 3: Rates of local, regional, and distant control as estimated by
cumulative incidence.
Time (months) Local Control Locoregional
Control Distant Control
24 92.2%
(69.2–99.6%)
92.2%
(69.2–99.6)
85.9%
(62.7–98%)
60 81.0%
(51.2–97.9%)
58.7%
(29.4–89.4%)
85.9%
(62.7–98%)
Disease freedom, censoring deaths due to unrelated causes,
was 78.1% at 2 years and 44.6% at 5 years (Table 4, Figure 1).
Overall survival rates were 64.7% at 2 years and 51.5% at 5
years (Table 4, Figure 2).
4. Discussion
Both historical and modern series demonstrate that mucosal
melanomas of the head and neck remain a particularly
aggressive malignancy. Due to their propensity to recur
distantly in addition to locally, they exhibit even more
aggressivebehaviorthantypicalheadandneckmalignancies.
The optimal treatment regimen for patients remains unclear
as there are no prospective data, nor even a comprehensive
stagingsystem,forthisraredisease.Depthofinvasion,which
isawellestablishedelementofriskstratiﬁcationincutaneous
disease, is diﬃcult to evaluate and thus not well studied in
mucosal primaries. The lack of clearly deﬁned prognostic
indicatorsmakesitdiﬃculttoassesswhichpatientsmaytruly
beneﬁt from more aggressive treatment regimens. Earlier,
primary site of disease was felt to be an important prognostic
indicator, with sinonasal primaries having a poorer outcome
than lesions originating in the oral cavity [3]. However,
this has not been supported consistently by more modern
reports, which suggest that the survival is similar for all head
and neck primary sites [5, 10].
4.1.SurgeryandPosoperativeRadiationTherapy. Wide surgi-
calresectionhasbecomethemainstayofinitialtherapywhen
feasible [11]. However, the types of en-bloc tumor resections
which allow wide surgical margins typically employed in
cutaneous melanoma are often not feasible in head and
neck mucosal primaries, due to their proximity to critical
normal structures. While advances in surgical technique
have enabled more aggressive local resections in large part
Table 4: Kaplan Meier estimates of disease-freedom and overall
survival.
Time (months) Disease freedom Overall survival
24 78.1%
(56–92.5%)
64.7%
(37.7–82.3%)
60 44.6%
(14.6–71.3%)
51.5%
(25.7–72.3%)
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Figure 1: Disease-freedom.
due to the advent of more sophisticated reconstruction
techniques such as microvascular-free tissue transfer, these
techniques still do not allow the uniform application of wide
(1.5 to 2cm) resection margins in these locations.
Postoperative RT has shown to improve local control in
several retrospective series [5, 10]. Whether this improve-
ment translates to an improvement in prognosis remains
unclear however, as only one report has demonstrated an
o v e ralls urvi valbe ne ﬁtwiththeuseo fpost o pe rati v eR T[12].
Improved local control likely corresponds with improved
outcomes, as was seen in the Mandolis meta-analysis in
which rates of distant metastasis were 73.1% in patients
with local failure while 52.1% in those with local control
[3]. This series suggested that local failure portends distant
failure, which is often lethal. Individual series, however, have
not consistently shown this relationship between local and
distant control [13].
The inability of individual series to demonstrate sig-
niﬁcant overall advantages with the addition of RT is
skewed by the inherent selection bias each retrospective
analysis, in which patients with more extensive disease
were often treated more aggressively. Postoperative RT may
therefore potentially beneﬁt patients, despite retrospective
series paradoxically reporting better outcomes in patients
treated with surgery alone. Our data suggests that the
addition of conventionally delivered RT leads to improved
local control, as all three patients who recurred locally had
not received postoperative RT to the tumor bed.ISRN Oncology 5
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Figure 2: Overall survival.
4.2. Elective Nodal Irradiation. W h i l ei ta p p e a r st h a tR Tt o
the postoperative bed improved local control, the potential
beneﬁt of regional RT is less clear. In a series from the Uni-
versityofFlorida,surgeryfollowedbypostoperativeRTledto
improved local control versus deﬁnitive RT. Additionally, six
patients received elective nodal RT to clinically uninvolved
cervical nodal regions. A trend towards improvement in
regional control was observed with the addition of neck
irradiation at 2.5 years.
The authors of this University of Florida series agree
that surgery with postoperative RT should be used in nearly
all cases of head and neck mucosal melanomas. However,
they also suggest that elective nodal irradiation should be
used to address subclinical regional disease. Incidentally, this
recommendation is based upon very small patient numbers,
with regional control being achieved in 5/6 patients receiving
elective neck RT, versus 6/8 patients not receiving elective
nodal therapy [14].
In our series, 16/17 patients did not receive elective
nodal RT. Only two patients failed regionally and were
successfully salvaged with long-term control with aggressive
therapy. Therefore, we do not presently recommend routine
elective nodal irradiation of the neck, as the beneﬁts may not
outweigh its morbidity in all cases. Patients with oral cavity
primaries have a higher rate of cervical nodal metastasis
and should be evaluated on a case-by-case basis, with
considerationofelectivenodalirradiationbasedupontumor
size, location, and so forth. This conclusion suggested by our
data is in accord with the current NCCN practice guidelines
for this disease entity [15]. Sentinel lymph node biopsy,
which has become a mainstay in cutaneous melanoma
and is showing promise in head and neck squamous cell
carcinomas, may be of particular value in elucidating this
treatment dilemma [16].
4.3. Deﬁnitive Radiation Therapy. Due to the location and
extent of these tumors in the head and neck region, a wide
surgical resection is sometimes not possible without leaving
the patient with signiﬁcant functional or cosmetic deﬁcits.
For these reasons, deﬁnitive RT has been considered for
mucosal melanomas of the head and neck.
While initial response rates are reasonable, long-term
outcomes with photon irradiation have generally been poor.
This is often due to development of distant metastases
despite local disease control [17]. Due to the potential
radioresistance of melanoma cells, hypofractionated regi-
mens and dose-escalation have been adopted order to more
eﬀectivelyeradicatetheprimarytumor.Theseregimensmust
be used with caution in head and neck sites, however, to
avoid signiﬁcant late toxicities of RT. Modern RT delivery
however, including stereotactic techniques, may allow for
dose escalation and/or hypofractionation, while preferen-
tially sparing surrounding normal tissues.
HigherlinearenergytransferRThasalsobeenconsidered
in this setting. In addition to the physical advantage of
greater energy deposition per unit length, proton and heavy
ion beams also have a spatial selectivity due to their ﬁnite
rangeanddepth-dosedistribution[18].Thisdosedeposition
proﬁle is of particular interest in the head and neck region,
where critical normal structures often lie adjacent to the
tumor itself.
In a recent report from Japan, carbon ion beams were
used as deﬁnitive therapy for previously untreated mucosal
melanomas of the head and neck. Five-year local control rate
for patients was 84.1%, while ﬁve-year overall survival was
estimated at 27%, with minimal severe long-term toxicities.
Distant metastases occurred in 56% of patients overall,
however, corresponding to the overall survival described
above. However, 34/40 patients in this series who developed
distant metastases were without local recurrence, which
depicts the eﬃcacy of this therapy in terms of local control
[19].
The rate of local control described the Japanese series
with radiation alone is at par with most surgical series, while
o v e r a l ls u r v i v a li ss i m i l a r[ 3, 5, 10]. Given the potential
morbidities of surgery in this disease, deﬁnitive RT with
heavy ions should be considered as a noninvasive approach
in patients unable to undergo surgery. Unfortunately, carbon
ion therapy is of limited use in the postoperative setting, as
the increased biological eﬀect can be deleterious to normal
tissues.
4.4. Systemic Therapies. While local and regional control
may be improved with advancements in surgical and radi-
ation delivery techniques, the poor prognosis of this rare
disease centers upon the rate of distant metastases. The
early presentation of distant disease, even with adequate
local control, suggests the need for early intervention with
systemic therapies.
Initial results with traditional chemotherapeutic agents
in both cutaneous and mucosal variants of melanoma have
beendisappointing[20].Thishasledtoamovementtowards
immunotherapies in melanoma and other resistant tumors,
in an eﬀort to modulate the patient’s own immune system
to respond to the tumor cells as a foreign entity [3]. These6 ISRN Oncology
therapiescouldpotentiallybedeliveredconcurrentlywithRT
to further enhance tumor cell damage.
In the current series, seven of 17 patients received
immunotherapyintheadjuvantsetting,whileoneadditional
patient was treated in the salvage setting. Our improvement
in 5-year survival compared to historical series may be
in part due to the early use of systemic therapies which
may have potentially prevented distant metastatic disease
from presenting or addressed subclinical disease prior to it
becoming apparent. Our data also shows that while local
and regional failures can be successfully salvaged, it remains
diﬃcult to provide disease control once distant metastases
are present. A detailed analysis of systemic therapies is
certainly beyond the scope of this paper, but our results
are hypothesis generating in terms of the beneﬁt of early
adjuvant systemic therapies.
4.5. Limitations. This analysis is clearly limited by its retro-
spective nature, small patient numbers, and lack of formal
toxicity data with grading for all patients. It is unique,
however, in terms of its modern treatment techniques and
use of systemic therapies. While the patient number may
appear small, it represents the patient volume of a single
institution with an active head and neck cancer program and
issimilartootheranalysesthatincludedpatientstreatedover
longer time frames [3, 14]. Although we do not have graded
toxicity data, severe functional toxicities such as blindness
or damage to the brainstem were not noted in any patients.
This is as expected since patients were generally treated
with3D-conformalorintensitymodulatedradiationtherapy
(IMRT).
5. Conclusions
Mucosal melanomas of the head and neck remain a rare
disease entity with an aggressive natural history and poor
long-term prognosis. The mainstay of therapy remains
deﬁnitive surgery followed by postoperative RT to the tumor
bed. This aggressive multimodality approach appears to
improve local control, even in patients with advanced disease
at presentation. This improvement in local control has not
necessarily correlated with improved overall outcomes in
individual retrospective series, however, due to limitations
of each series. Given the lower rates of cervical nodal
metastases, particularly in the case of sinonasal disease, as
well as the potential for long-term control after successful
salvage therapy at the time of neck failure, we currently do
not recommend the routine use of elective neck irradiation.
Heavy-ion therapy, although not widely available, has been
shown to provide similar control rates to surgery followed by
photon irradiation. It should be considered particularly in
patients who have unresectable disease or are unsuitable for
surgery.Ourimprovementinoverallsurvivalratescompared
to historical series may reﬂect improvements in delivery of
local therapies in the modern era, as well as the advent
of systemic therapies which prevent locoregional recurrence
and distant dissemination of disease.
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